Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
34 participants
INTERVENTIONAL
2023-08-22
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Determine the impact of combined LVR and EMST on cough strength and respiratory function in individuals with ALS.
2. Determine the impact of combined LVR and EMST on patient-reported dyspnea and bulbar impairment.
3. Describe the effect of combined LVR and EMST on patient- and caregiver reported burden and quality of life.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Timeline.
Study assessments and procedures at each time point are briefly described below and depicted in Table 1.
Screening/Baseline 1 (Week -5).
Following consenting and screening procedures, study personnel will complete the initial baseline assessment procedures. Participants will complete the initial baseline assessment in approximately 60-90 minutes.
Baseline 2 (Week 0).
The Baseline 2 appointment will consist of the identical assessment procedures conducted in the same order as Baseline 1. LVR and EMST training will be introduced and the first training session will be completed during the appointment. Participants will complete the Baseline 2 appointment in \~100-120 minutes.
Telehealth Appointments (Active Training Weeks 0-5).
Weekly telehealth therapy appointments will be conducted during the active training period using the Zoom platform (Zoom Video Communications, Inc). During these sessions, the research clinician will lead a LVR and EMST training session with the participant, complete peak cough flow and maximum sustained phonation testing, and administered surveys including the ALS Functional Rating Scale- Revised and the ALS Respiratory Symptom Scale. Surveys will be screen shared with the participants and data will be recorded on the source documents by the research clinician.
Final Evaluation (Week 5).
The Final Evaluation appointment will consist of the identical assessment procedures conducted in the same order as Baseline 2.
Follow-up Period (6-months).
The follow-up period consists of monthly telehealth visits with the research clinician. Participants who complete the initial 10-week study period will be asked to participate in follow-up. These telehealth visits will include peak cough flow and maximum phonation time assessments, and clinician-administered surveys. During this period, treatment adherence will be tracked using the same daily treatment logs, which will be reviewed during monthly appointments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung Volume Recruitment +Expiratory Muscle Strength Training
All enrolled participants will commence a combined lung volume recruitment and expiratory muscle strength training exercise regimen following a 5-week no-intervention lead-in period.
Respiratory Muscle Strength Training (LVR+EMST)
Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Respiratory Muscle Strength Training (LVR+EMST)
Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Disease duration from symptom onset of ≤ 2 years,
3. Lung volume recruitment and expiratory muscle strength training naïve,
4. Reduced peak cough flow (% predicted for age and gender).
Exclusion Criteria
2. Use of prescription cough assist or non-invasive volume ventilation devices.
3. Enrollment in another research investigation that might impact cough or respiratory function.
4. Diagnosis of frontotemporal dementia or advanced cognitive impairment.
5. Tracheostomy placement/Use of invasive mechanical ventilation.
6. Contraindications for respiratory training (i.e., history of pneumothorax, severe chronic obstructive pulmonary disease).
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Congressionally Directed Medical Research Programs
FED
Nova Southeastern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lauren Tabor Gray, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Magalie Thomas, MBA
Role: STUDY_CHAIR
Nova Southeastern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nova Southeastern University
Fort Lauderdale, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lauren Tabor Gray, PhD
Role: primary
Donovan Mott
Role: backup
Related Links
Access external resources that provide additional context or updates about the study.
Nova ALS Clinic
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AL220099
Identifier Type: -
Identifier Source: org_study_id